Abstract:Breast cancer is the most common malignancy diagnosed in US women and is the second leading global cause of death for women. Triple Negative Breast Cancer (TNBC) is a more aggressive subtype of breast cancer that is categorized by negative expression of estrogen receptors, progesterone receptors, and amplification of HER2/neu. Because of its receptor phenotype, traditional hormone therapy fails to produce significant short- or long-term benefits for patients. Additionally, chemotherapeutic and surgical interventions often result in relapse and development of a more aggressive disease with higher rates of growth, metastasis, and drug resistance. TNBC also tends to affect women younger than 40 as well as black women, making it a disease of disparities. The Liver Kinase B1 (LKB1/STK11) signaling pathway has been well characterized to have a role in defining cellular responses to energy homeostasis, metabolism, as well as tumor suppressive capabilities. It functions as a master regulator through a set of 14 known kinase targets to maintain its role in cell-type specific regulation. Peutz Jeghers Syndrome, a genetic disorder with a predisposition to developing malignancies, and many other solid tumor cancers are associated with a loss of expression, somatic mutation, or functional deficiencies of LKB1 activity. While studies have been done to understand the role of LKB1 signaling, its role and mechanism in the regulation of TNBC remains unknown. We previously demonstrated LKB1 expression to be associated with increased survival rates for patients diagnosed with TNBC. Therefore, we hypothesize that LKB1 activity in TNBC cell lines will inhibit cancer function. To test this, TNBC cell lines were transfected to overexpress LKB1 with vector transfections generated for controls. Initial molecular results demonstrate a reversal of EMT gene expression by qPCR in cells that overexpressed LKB1. Flow cytometry analysis of LKB1 overexpressing cells show a decrease in the GD2+ cancer stem cells (CSCs). Additionally, functional assays show a reduction growth and proliferation in 3D culture systems. Interestingly, there was no effect on proliferation in standard 2D culture conditions. GD2 was previously identified to be regulated by NFkB signaling. Because LKB1 overexpression resulted in the suppression of CSCs, we hypothesized that LKB1 expression suppresses NFkB signaling. To test this, we ran a western blot panel for NFkB antibodies. Interestingly, LKB1 OE cells had lower levels of IKKα, IKKß, and p65 compared to pcDNA controls. This suggests that LKB1 functions to inhibit NFkB signaling, resulting in the suppression of the CSC phenotype in TNBC. To summarize, LKB1 expression inhibits NFkB signaling, which leads to decreased CSCs. This results in reversal of EMT genes and diminished capabilities to form spheres. Future studies will be dedicated to identifying which of the 14 downstream kinases LKB1 activates to exert its functions. Citation Format: Khoa Nguyen, Madlin Alzoubi, Thomas Cheng, Katherine Hebert, Steven Elliott, Hassan Yousefi, Suresh Alahari, Matthew Burow, Bridgette Collins-Burow. LKB1 inhibits NFkB to suppress cancer stem cells in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 863.

Lkb1 Regulates Cox-2 Transcription Via Crtcs Dependent Pathway

Cleavage and Polyadenylation Specific Factor 4 Targets NF-κB/cyclooxygenase-2 Signaling to Promote Lung Cancer Growth and Progression

Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation

Putative Tumor-Suppressive Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma

KLF4 Downregulates Htert Expression and Telomerase Activity to Inhibit Lung Carcinoma Growth.

LKB1 Inhibits Lung Cancer Progression Through Lysyl Oxidase and Extracellular Matrix Remodeling.

LKB1 and lung cancer: more than the usual suspects

Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Deregulation of Casein Kinase-2 in Non-Small-cell Lung Cancer: A Subunit-Specific Analysis

Abstract 5829: Elucidating the significance of amphiregulin and its implications for EGFR inhibition strategies in LKB1-mutant NSCLC

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

Liver Kinase B1 (LKB1) Regulates Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells via Targeting ERK Signaling Pathway

Abstract 348: LKB1 Deficiency Confers Lung Adenocarcinoma Phenotypic Plasticity with Squamous Transdifferentiation Potential.

Patient profiles at a centralized, urban, diabetes education centre.

Abstract 4322: Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer

Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Hnrnpa2/b1 Activates Cyclooxygenase‐2 and Promotes Tumor Growth in Human Lung Cancers

Abstract 863: LKB1 inhibits NFkB to suppress cancer stem cells in triple negative breast cancer

PKNOX2 suppresses lung cancer cell proliferation by inhibiting the PI3K/AKT/mTOR axis

Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer